TIDMAPH

RNS Number : 3666Y

Alliance Pharma PLC

02 January 2024

 
 For immediate release   02 January 2024

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Block Listing Six Monthly Return

 
 Name of applicant:                                     ALLIANCE PHARMA PLC 
 Names of schemes:                                      a) The Alliance Pharma plc Approved Share Option Plan 2005 
                                                         b) The Alliance Pharma plc Share Option Plan 2006 
                                                         c) The Alliance Pharma plc Company Share Option Plan 2015 
                                                         d) The Alliance Pharma plc Long-Term Incentive Plan 2019 
                                                       --------------------------------------------------------------- 
 Period of return:              From:                   28 June 2023             To:      31 December 2023 
                               ----------------------  -----------------------  -------  ----------------------------- 
 Number of securities originally admitted at date of    25,000,000 ordinary shares of 1p each 
 admission:                                              28 June 2017 
                                                       --------------------------------------------------------------- 
 Balance of unallotted securities under schemes from    a) 57,922 
 previous return:                                        b) 2,487,746 
                                                         c) 9,572,622 
                                                         d) 1,341,116 
                                                       --------------------------------------------------------------- 
 Plus: The amount by which the block schemes have       a) Nil 
 been increased since the date of the last               b) Nil 
 return (if any increase has been applied for):          c) Nil 
                                                         d) Nil 
                                                       --------------------------------------------------------------- 
 Less: Number of securities issued/allotted under       a) 0 
 schemes during period:                                  b) 14,239 
                                                         c) 0 
                                                         d) 225,618 
                                                       --------------------------------------------------------------- 
 Equals: Balance under schemes not yet                  a) 57,922 
 issued/allotted at end of period:                       b) 2,473,507 
                                                         c) 9,572,622 
                                                         d) 1,115,498 
                                                       --------------------------------------------------------------- 
 
 
 
 Name of contact:               Chris Chrysanthou, Company Secretary 
 Telephone number of contact:   Tel. +44 (0)1249 705166 
                               -------------------------------------

For further information:

 
 Alliance Pharma plc                          + 44 (0)1249 466966 
 Head of Investor Relations: Cora McCallum    + 44 (0)1249 705168 
 ir@allianceph.com 
 
                                                  + 44 (0)20 7466 
 Buchanan                                                    5000 
 Mark Court / Sophie Wills 
 alliancepharma@buchanan.uk.com 
 
 Deutsche Numis (Nominated Adviser and            + 44 (0)20 7260 
  Joint Broker )                                             1000 
 Nominated Adviser: Freddie Barnfield / 
  Duncan Monteith / Sher Shah 
 
                                                  + 44 (0)20 7597 
 Investec Bank plc (Joint Broker)                            5970 
 Patrick Robb / Maria Gomez de Olea

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company . Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions .

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRUUSRRSNUARAR

(END) Dow Jones Newswires

January 02, 2024 05:51 ET (10:51 GMT)

Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Alliance Pharma Charts.
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Alliance Pharma Charts.